Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
    • Founders
    • A word from the CEO
  • Antibiotics
    • About
    • Antimicrobial resistance
    • Portfolio
    • The AGIR program
    • Discovery platform
    • Partners
  • Bioactives
    • About
    • Biodiversity
    • Portfolio
    • Platform of Expertise
    • Partners
  • Investor room
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News & events
    • Press releases
    • Events
    • Press coverage
  • Careers
    • Join DEINOVE
    • Open positions
  1. Home
  2. Investor room
  3. Press releases

Press releases

26.09.2019

2019 Half-year consolidated results: Deinove’s progress coming to fruition

Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...
09.07.2019

Issuance of notes convertible into new shares for a maximum amount of €15M. Issuance of a first €2.2 million tranche

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
28.03.2019

2018 Annual Results: a year of significant progress

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium...
21.11.2018

DEINOVE confirms its financing options by renewing its equity line

The equity line funding set up in December 2014 expired. It has enabled DEINOVE to raise €9.4 million net in a flexible, optimized manner...
27.09.2018

2018 half-year consolidated results: strengthened financial situation, substantial progress in both areas of business

Cash position: +€9.9m at June 30, 2018 compared to +€4.9m at December 31, 2017 thanks to the reinforcement of shareholders' equity Half-...
15.06.2018

DEINOVE: Successful capital increase of € 8.5 million

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...
23.05.2018

General meeting of May 23: Shareholders approve the acquisition of MORPHOCHEM

The General Meeting approved the contribution in kind of the BIOVERTIS (parent company of MORPHOCHEM) shares and options and the issuance...
13.04.2018

DEINOVE takes on a whole new dimension with the acquisition of MORPHOCHEM’s clinical-stage antibiotic compound

MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...
29.03.2018

2017: ambitions confirmed, milestones reached, and financial results in line with the development strategy

Acceleration of the Antibiotics program: €14.6m of funding by Bpifrance (including € 10.4m for the DEINOVE Group) and structuring of the...
28.09.2017

2017 half-year consolidated results: stability of net loss major progress on R&D programs in health, nutrition and cosmetics

Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016. Half-year net loss of DEINOVE Group (composed of DEINOVE...
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • next ›
  • last »

Investor room

  • Corporate governance
    • Board of Directors
    • Executive Committee
  • DEINOVE Shares
  • Financial Calendar
  • Documentation Center
    • Financial Reports
    • Investor presentations
    • Analyst Coverage
    • Newsletter to Shareholders
    • Shareholders' Meetings
    • Shares and Voting Rights
    • Transactions on company securities
    • Liquidity Agreement
    • Public offerings - Documentation
    • Obligations Convertibles en Actions (OCA)
  • Press releases
  • Investor relations
  • Contact
  • Location
  • Legal Info
  • Site map
  • Privacy Policy

Profile

  • About DEINOVE
  • Board of Directors
  • Executive Committee
  • Founders
  • A word from the CEO

Antibiotics

  • About
  • Antimicrobial resistance
  • Portfolio
  • The AGIR program
  • Discovery platform
  • Partners

Bioactives

  • About
  • Biodiversity
  • Portfolio
  • Platform of Expertise
  • Partners

Investor room

  • Corporate governance
  • DEINOVE Shares
  • Financial Calendar
  • Documentation Center
  • Press releases
  • Investor relations

Careers

  • Join DEINOVE
  • Open positions

News & events

  • Press releases
  • Events
  • Press coverage

Downloads

  • Investor presentations
  • Analyst Coverage
  • Financial Reports

Follow us

Stay in touch

Subscribe to our newsletter

Contact us

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home